This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Heidelberg Immunotherapeutics Gmbh, Rheinische Friedrich-Wilhelms-Universitat Bonn, Roche Diagnostics Gmbh. Active years: 2000-2017.
Company Filing History:
1 out of 1 
1 out of 31 
1 out of 485 
Years Active: 2000-2017
Title: Michael Roggendorf: Innovator in Anti-HSV Antibody Research
Introduction
Michael Roggendorf is a notable inventor based in Essen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of anti-HSV antibodies. With a total of 3 patents to his name, Roggendorf's work is pivotal in advancing therapeutic options for HSV-associated diseases.
Latest Patents
Roggendorf's latest patents focus on an anti-HSV antibody. The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising an effective amount of the said antibody, an expression vector comprising a nucleotide sequence that encodes the said antibody, a host cell comprising the said nucleotide sequence, and a hybridoma cell capable of producing the said antibody. The use of this antibody as a drug is particularly aimed at the prophylactical or therapeutical treatment of HSV-associated diseases in a subject, as defined in the claims.
Career Highlights
Throughout his career, Michael Roggendorf has worked with prominent organizations such as Heidelberg Immunotherapeutics GmbH and Universität Duisburg Essen. His experience in these institutions has allowed him to refine his expertise in antibody research and development.
Collaborations
Roggendorf has collaborated with esteemed colleagues, including Anna-Maria Eis-Hübinger and Jürgen Krauss. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Michael Roggendorf's innovative work in the field of anti-HSV antibodies showcases his commitment to improving therapeutic options for patients. His contributions are vital in the ongoing fight against HSV-associated diseases.